Ranbaxy Of India Seeks To Rebuild Relations With U.S. FDA
This article was originally published in PharmAsia News
Executive Summary
India's Ranbaxy Laboratories says in its annual report it plans to rebuild its strained relationship with U.S. FDA. Malvinder Mohan Singh, CEO and managing director of Ranbaxy, wrote in the report the company's focus is to be on resolving FDA's issues of compliance and good manufacturing practices. The company has plans to acquire FDA-approved manufacturing facilities to produce drugs once made at a pair of plants the FDA blacklisted. (Click here for more